Cambridge Heart Adds New Director; Robert DePasqua Joins Company's Board

BEDFORD, Mass.--Nov. 1, 20038, 2003--Cambridge Heart, Inc. (OTCBB-CAMH) announced today Robert J. DePasqua has been joined the Company's Board of Directors increasing the number of Directors to seven.

Mr. DePasqua has over thirty years of management experience in both public and private companies. His experience encompasses many different types of high-tech, value added, medical devices including traditional surgical instruments, orthopedic implants, bio adhesives and cardiovascular and endoscopic disposable products. Over the course of his career he has directly raised over $70 million in IPO and venture capital. Mr. DePasqua was one of the first employees of Boston Scientific Corporation and served in a number of senior management positions during his ten year tenure including President and founder of Microvasive, Inc. He has also served as the President and CEO of Spectranetics Corporation, Focal Inc., Biolink Corporation, Betagen Corporation and EndoVia Medical Inc., all early stage public or private medical product companies. Mr. DePasqua is currently a member of the board of directors of Blackstone Medical, Inc., and has served in the past as an independent board member of Spinetech, Inc., Tetrad Incorporated and Newmed, Inc.

"Bob DePasqua comes to our board with years of experience having successfully met many of the same operational and strategic challenges we are faced with on a daily basis," said David Chazanovitz, President and CEO of Cambridge Heart. "He will be able to provide valuable operational insight and guidance as we continue to grow our Microvolt T-Wave Alternans business."

About the Cambridge Heart Microvolt T-Wave Alternans Test

The Cambridge Heart Microvolt T-Wave Alternans Test measures extremely subtle beat-to-beat fluctuations in a person's heartbeat called T-wave alternans. These tiny heartbeat variations - measured at one millionth of a volt - are detected in any clinical setting where titration of the heart rate is possible. The preparation for the test consists of placing proprietary sensors on a patient's chest. Extensive clinical research has shown that patients with symptoms of or at risk of life threatening arrhythmias who test positive for T-wave alternans are at significant risk for subsequent sudden cardiac events including sudden death, while those who test negative are at minimal risk.

About Cambridge Heart

Cambridge Heart is engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease. Using innovative technologies, the company is addressing such key problems in cardiac diagnosis as the identification of those at risk of sudden cardiac arrest. The Company's products incorporate its proprietary technology, Microvolt T-Wave Alternans, and are the only diagnostic tools cleared by the U.S. Food and Drug Administration to non-invasively measure microvolt levels of T-wave alternans. The Company, founded in 1990, is based in Bedford, Massachusetts and is traded on the NASDAQ/SmallCap under the symbol CAMH. Cambridge Heart can be found on the World Wide Web at www.cambridgeheart.com.

Statements contained in this press release about anticipated revenue growth, and all other statements that are not purely historical, are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. In some cases, we use words such as "believes", "expects", "anticipates", "plans", "estimates" and similar expressions that convey uncertainty of future events or outcomes to identify these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements. Factors that may cause or contribute to such differences include failure to obtain funding necessary to develop or enhance our technology, adverse results in future clinical studies of our technology, failure to obtain or maintain patent protection for our technology, failure to obtain or maintain adequate levels of third-party reimbursement for use of our products and other factors identified in our most recent Quarterly Report on Form 10-Q under "Factors Which May Affect Future Results", which is on file with the SEC. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change.